{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:13:12Z","timestamp":1790057592152,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.lfs.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T10:55:04Z","timestamp":1557399304000},"page":"251-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice"],"prefix":"10.1016","volume":"228","author":[{"given":"Warinda","family":"Susutlertpanya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kuramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masae","family":"Kuranari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2019.05.014_bb0005","first-page":"OC04","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with diabetic nephropathy in patients with type 2 diabetes mellitus","volume":"11","author":"Heidari","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.lfs.2019.05.014_bb0010","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1872-034X.2011.00824.x","article-title":"NASH: a global health problem","volume":"41","author":"Sanyal","year":"2011","journal-title":"Hepatol. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2019.05.014_bb0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.13301","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"37","author":"Bedossa","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.lfs.2019.05.014_bb0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","article-title":"Liver transplantation for nonalcoholic steatohepatitis: the new epidemic","volume":"256","author":"Agopian","year":"2012","journal-title":"Ann. Surg."},{"key":"10.1016\/j.lfs.2019.05.014_bb0025","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.3748\/wjg.v20.i42.15532","article-title":"Liver transplantation and non-alcoholic fatty liver disease","volume":"20","author":"Zezos","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4254\/wjh.v6.i5.263","article-title":"Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations","volume":"6","author":"Wong","year":"2014","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0035","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41395-018-0373-4","article-title":"Non-alcoholic steatohepatitis as a growing indication for liver transplantation: the evolving gender and ethnic trends","volume":"113","author":"Wieland","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0040","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","article-title":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","volume":"22","author":"Hansen","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2019.05.014_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.drudis.2015.10.015","article-title":"Emerging therapeutic targets for the treatment of hepatic fibrosis","volume":"21","author":"Fagone","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2019.05.014_bb0050","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2019.05.014_bb0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2019.05.014_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/srep44545","article-title":"Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model","volume":"7","author":"Ozturk Akcora","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2019.05.014_bb0065","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41416-018-0051-8","article-title":"A multicentre, open-label, phase-I\/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma","volume":"118","author":"Palmer","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2019.05.014_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000486460","article-title":"A phase I\/randomized phase II study to evaluate the safety, pharmacokinetics, and efficacy of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma","volume":"7","author":"Yen","year":"2018","journal-title":"Liver Cancer"},{"key":"10.1016\/j.lfs.2019.05.014_bb0075","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/cas.13077","article-title":"Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment","volume":"107","author":"Okusaka","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lfs.2019.05.014_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.lfs.2019.05.014_bb0090","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1681\/ASN.2012020126","article-title":"PGD2-CRTH2 pathway promotes tubulointerstitial fibrosis","volume":"23","author":"Ito","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004249","article-title":"The impact of juvenile coxsackievirus infection on cardiac progenitor cells and postnatal heart development","volume":"10","author":"Sin","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2019.05.014_bb0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/019262338301100204","article-title":"Comparison of fresh and fixed organ weights of rats","volume":"11","author":"Kanerva","year":"1983","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/03014223.1985.10428276","article-title":"Effect of storage in formalin on organ weights of rabbits","volume":"12","author":"Fraser","year":"1985","journal-title":"New Zeal. J. Zool."},{"key":"10.1016\/j.lfs.2019.05.014_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.metabol.2016.12.013","article-title":"Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice","volume":"69","author":"Honda","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2019.05.014_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/iep.12240","article-title":"Hepatocellular carcinoma in a mouse model fed a choline-deficient, l-amino acid-defined, high-fat diet","volume":"98","author":"Ikawa-Yoshida","year":"2017","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0120","first-page":"626","article-title":"Alkaline phosphatase: can it be considered as an indicator of liver fibrosis in non-alcoholic steatohepatitis with type 2 diabetes?","volume":"112","author":"Kocabay","year":"2011","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.lfs.2019.05.014_bb0125","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2337\/dc14-1239","article-title":"Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD","volume":"38","author":"Bazick","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2019.05.014_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/srep40977","article-title":"Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis","volume":"7","author":"Hall","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2019.05.014_bb0135","first-page":"4191","article-title":"Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease","volume":"7","author":"Aida","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.lfs.2019.05.014_bb0140","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jceh.2017.05.084","article-title":"Cytokeratin-18 (CK-18) is a useful biomarker in differentiating between NASH and No-NASH amongst patients with nonalcoholic fatty liver disease (NAFLD)","volume":"7","author":"Mehta","year":"2017","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0016-5085(03)00907-7","article-title":"Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis","volume":"125","author":"Feldstein","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2019.05.014_bb0150","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.cgh.2008.07.016","article-title":"Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients","volume":"6","author":"Diab","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0155","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.lfs.2019.05.014_bb0160","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2036.2010.04556.x","article-title":"Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"33","author":"Dowman","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2019.05.014_bb0165","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann. Med."},{"key":"10.1016\/j.lfs.2019.05.014_bb0170","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.lfs.2019.05.014_bb0175","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.05.014_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2019.05.014_bb0185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2019.05.014_bb0190","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fphys.2012.00248","article-title":"Liver fibrogenesis in non-alcoholic steatohepatitis","volume":"3","author":"Bian","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0195","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","article-title":"Mechanisms of hepatic fibrogenesis","volume":"25","author":"Lee","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.lfs.2019.05.014_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lfs.2019.05.014_bb0210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"15","author":"Hostettler","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.lfs.2019.05.014_bb0215","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.05.014_bb0220","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.05.014_bb0225","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2217\/fon-2016-0067","article-title":"Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519303601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519303601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:23:35Z","timestamp":1758399815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320519303601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":45,"alternative-id":["S0024320519303601"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2019.05.014","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}